摘要
目的:探讨131I治疗Graves病甲状腺机能亢进症(Graves病甲亢)的远期疗效和并发症发生情况。方法:对接受131I治疗的Graves病甲亢患者进行5年随访,治愈率、有效率和甲减发生率采用生存分析(寿命表法)进行统计处理。结果:543例患者,391例行一次治疗,152例行两次治疗,共失访78例(失访率14.4%),5年总有效率89.2%,总治愈率83.3%,复发率2.9%。131I治疗后1年和5年的甲减累积发生率分别为11.4%和26.4%,一次治疗和两次治疗的5年甲减累积发生率分别为25.4%和28.7%,无显著差异(P=0.410)。结论:131I治疗Graves病甲亢有效、安全,甲减是其主要并发症,发生率呈逐年增加趋势,两次治疗并不增加甲减的发生。
Objective：To study the long term effect and complications of radioiodine therapy for patients with Graves＇ hyperthyroidism.Methods：To follow up the patients with Graves＇hyperthyroidism who reveived radioiodine therapy for 5 years and to analyse the cure rate,the effective rate and the hypothyroid rate by survival analysis.Results：Three hundred and ninty-one of 543 patients reveived the first therapy,152 of 543 paitents received the second therapy.Seventy-eight patients hadn＇t been followed up（14.4%）.In five years,total effective rate,total cured rate and the relapse rate were respectively 89.2%,83.3%and 2.9%.The hypothyroid rate in 1 year and 5 years were respectively 11.4% and 21.4%.The hypothyroid rate were respectively 11.4%（received the first therapy）and 26.4%（received the second therapy）.No significant difference were found in the hypothyroid rate between the first therapy（25.4%）and the second therapy（28.7%）.Conclusion：Radioiodine therapy is a safe and efficient strategy for patients with Graves＇hyperthyroidism.
出处
《华西医学》
CAS
2008年第2期272-273,共2页
West China Medical Journal
